anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Several international epidemiological studies have established a link between obesity and upper gastrointestinal cancer (UGC), but Chinese evidence is limited. This study aimed to determine the prevalence of obesity, especially central obesity, while investigating its association with upper gastrointestinal diseases in the high-risk population of Yangzhong, a typical high-risk area for UGC in southeastern China. We conducted a cross-sectional study from November 2017 to June 2021 involving 6736 residents aged 40-69. Multivariate logistic regression was used to assess independent factors influencing overweight/obesity and central obesity. We also analyzed the relationship between obesity and upper gastrointestinal diseases using multinomial logistic regression. The prevalence of overweight, obesity, waist circumference (WC), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR)-central obesity were 40.6%, 12.0%, 49.9%, 79.4%, and 63.7%, respectively. Gender, age, smoking, tea consumption, sufficient vegetable, pickled food, spicy food, eating speed, physical activity, family history of cancer, and family history of common chronic disease were associated with overweight /obesity and central obesity. Besides, education and missing teeth were only associated with central obesity. General and central obesity were positively associated with UGC, while general obesity was negatively associated with UGC precancerous diseases. There were no significant associations between obesity and UGC precancerous lesions. Subgroup analyses showed that general and central obesity was positively associated with gastric cancer but not significantly associated with esophageal cancer. Obesity is negatively and positively associated with gastric and esophageal precancerous diseases, respectively. In conclusion, general and central obesity were at high levels in the target population in this study. Most included factors influenced overweight/obesity and central obesity simultaneously. Policymakers should urgently develop individualized measures to reduce local obesity levels according to obesity characteristics. Besides, obesity increases the risk of UGC but decreases the risk of UGC precancerous diseases, especially in the stomach. The effect of obesity on the precancerous diseases of the gastric and esophagus appears to be the opposite. No significant association between obesity and upper gastrointestinal precancerous lesions was found in the study. This finding still needs to be validated in cohort studies.
<P>PROBLEM TO BE SOLVED: To provide multiphase personal washing bars having artisan-crafted appearance.  <P>SOLUTION: In such bars the hardness of a discontinuous phase is greater than 2 times the hardness of a continuous phase. A manufacturing method of these by a high speed extrusion process comprises extruding a composition e.g. at least about 200 bars/minute, preferably in excess of 300 bars/minute. The bars made by the method comprise a discontinuous phase having its longest dimension between about 3 and about 75 mm that is dispersed in a continuous phase containing a cleansing base.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The present invention relates to solid dosage forms for parenteral delivery of therapeutic peptides. The substantially dry solid dosage forms comprise carboxymethylcellulose (CMC) which increases the strength, for example, compressive strength of the formulation, to enable reliable parenteral delivery. The solid dosage form comprises 0.01 to 50%(w/w) of a therapeutic peptide and at least 5%(w/w) of CMC excipient and has a moisture content of 5%(w/w) or less. The composition may further comprises a bulking agent, e.g. mannitol. The peptide may be octreotide, PTH 1-34 or exenatide. Also claimed is a method of producing the solid dosage form comprising blending the peptide, CMC and additional excipients, adding water to make a paste, extruding the paste to form an extruded product, drying the extruded product and cutting the product into solid dosage forms.
Methods and systems for calibrating billing cycles for remote monitoring patients and categorizing medical device interrogation data received from remotely monitored patients are disclosed. Interrogation data from a medical device may be received during a current billing schedule. Data from a patient profile may be processed. A determination may be made as to whether a patient's billing schedule corresponds to a first billing schedule or a second billing schedule. A determination may be made as to whether interrogation data from the medical device has been uploaded from a medical device within a current billing cycle preceding the current billing cycle. Upon determining that interrogation data from the medical device has not been uploaded from the medical device within the billing cycle preceding the current billing cycle, the patient's billing schedule may be adjusted such that a date on which interrogation data was received during the current billing schedule corresponds to the last day of the billing cycle preceding the current billing cycle.
Patients must be advised to dispose of any units remaining from a prescription as soon as they are no longer needed. While all units should be disposed of immediately after use, partially consumed units represent a special risk because they are no longer protected by the child resistant blister package, yet may contain enough medicine to be fatal to a child [see Patient Counseling Information (17.5)].

A temporary storage bottle is provided as part of the OTFC Child Safety Kit [see Patient Counseling Information (17.4)]. This container is to be used by patients or their caregivers in the event that a partially consumed unit cannot be disposed of promptly. Instructions for usage of this container are included in the Medication Guide.

Patients and members of their household must be advised to dispose of any units remaining from a prescription as soon as they are no longer needed. Instructions are included in Patient Counseling Information (17.6) and in the Medication Guide. If additional assistance is required, call Cephalon, Inc., at 1-800-896-5855.
An assay for compounds that interact with a cyclin by forming associations with the amino acids L253, I206 and R211 of cyclin A or their corresponding amino acids in other cyclins is claimed. Interactions between other amino acids in such cyclins may also form a part of the assay. These peptides may be peptides of SEQ ID NOS: 2 or 3 and retain the conserved motif XLXF. A large number of variants of these peptide sequences are also described and claimed. The assay may also include the step of using a three dimensional model of a cyclin. Independent claims also describe methods of screening for drugs that disrupt association with the specific amino acids described. The detection method for the assay may be by monitoring G0 and/or G1/S cell cycle, apoptosis, suppression of E2F hypophosphorylation of cellular pRb or in vitro anti-proliferative effects.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely gynaecology, physiotherapy. A method involves taking herbal tea, carrying out balneotherapy, phytoclay therapy, ozone therapy and cedar barrel. Sedative herbal tea contains motherwort, bugleweed, hop, toothwort and melissa. Diuretic and diaphoretic herbal tea contains tillet blossom and elderberry, bur marigold, coltsfoot and rose bay. While conducting phytoclay therapy and cedar barrel procedures, a herbal drug containing eucalyptus, common wormwood herb, sage, including clary, melilot and lavender. Said herbal drug is pre-divided into two portions. One portion is used to prepare an aqueous alcohol extract to be mixed with blue clay powder The other portion of the herbal drug is used to generate a therapeutic steam in a cedar barrel to be taken in a phyto cup. A therapeutic course is started with taking sedative herbal tea at bedtime as a depressant, while in the morning and in the afternoon, diuretic and diaphoretic herbal tea is taken. Therapeutic herbal teas are taken daily for the whole therapeutic course. Starting with the first day of treatment and further, the balneotherapeutic procedures are conducted in the form of malt baths every second day. The bath is prepared with using malt flower of barley at 250-300 g per 3 litres of hot water. The bath is taken for 20-30 minutes. Then the patient relaxes for 30-60 minutes. The malt bath is followed by conducting phytoclay therapy in the form of phytoclay applications on the 'panties' area. The same day, an ozone-oxygen mixture is injected subcutaneously in lipodystrophic areas. Starting from the fourth day and further every second say, intravenous ozone therapy is conducted. The phyto cup procedures are carried out on the same day. That is ensured by charging the second part of the vegetable drug stimulating microcirculation into a steam generator of a cedar barrel which is saturated with therapeutic steam. ^ EFFECT: method restores metabolic processes, normalises menstrual cycle. ^ 4 cl, 1 tbl, 3 ex
Etiological factors involved in myelodysplastic syndrome (MDS) include immunologic, oxidative stress and inflammatory factors, among others, and these are targets for microRNAs (miRNs). Here, we evaluated whether some miRNs may affect tumor development comparing untreated and 5-azacitidine (5-AZA) MDS-treated patients. Peripheral blood samples were collected from 20 controls and 24 MDS patients, and selected miRNs related to redox balance and inflammation (inflamma-miRs), including miR-18a, miR-21, miR-34a and miR-146a, were isolated and measured by quantitative real-time polymerase chain reaction (qRTPCR). A differential expression profile of miRNs was detected in untreated MDS patients and the 5-AZA group. Inflammation increases miRNs and, specifically, miR-18a, miR-21 and miR-34a were significantly overexpressed in untreated MDS, compared to controls. However, we did not observe any miRN profile alteration during the progression of the disease. On the other hand, 5-AZA treatment tends to restore miRN expression levels. Relating to prognostic risk factors, high-risk MDS groups (high Revised International Prognostic Scoring System (IPSS-R), high cytogenetic risk, high molecular risk (HMR) mutations) tended to be related with higher expression levels of miR-18a and miR-34a. Higher miRN expression is correlated with lower glutathione peroxidase activity, while they are related with a higher profile of pro-inflammatory cytokines (IL-2, IL-6, IL-8, TNF-α). Although our study was limited by the low number of MDS patients included, we identified miRN deregulation involved in MDS development that could regulate redox sensors and inflammatory responses. Finally, 5-AZA treatment is related with lower miRN expression levels in MDS patients.
Participants come from two clinics and will be randomly allocated to this group. Participants will go through a transition program which will last for 2 years. The intervention will be performed by specialist nurses (transition coordinators) who meet the participants at three occasions during the study period and participants will be offered to meet peers with type 1 diabetes during an adolescent day.
Aluminum contamination of parenteral nutrition (PN) solutions has been a concern for decades because of its link to metabolic bone disease (MBD) due to it's high aluminum content. Currently in the United States, FDA regulations are in place to protect American patients on PN from the effects of aluminum (AL) toxicity. Despite these regulations, pediatric patients on PN are still receiving higher than recommended AL intakes from PN.

Unlike the United States, there are no regulations governing AL content of or intakes from PN solutions in Canada. Consequently, the investigators are unaware of the AL content of the various PN solutions given to our patients. The investigators (the authors) have observed that a significant number of our patients on long-term PN (Home PN), have MBD. Some of our patients have also had bone fractures. The investigators have also observed alteration in calcium and phosphate concentrations as well as suppressed PTH. In an effort to understand the etiology of the MBD the investigators have measured serum AL concentrations in our patients and have found them to be high; between 900 - 2000 nmol/L compared to 0 to 220 nmol/L reported in healthy adults. This has led us to believe that there is a significant problem of AL contamination in PN solutions in Canada. Because the investigators are unable to obtain information on the AL content of the various PN solutions from the PN suppliers, the investigators have decided to report on the serum AL concentrations of our patients as well as the AL concentration of a random sample of PN solutions provided to patients. Plasma aluminum concentrations have already been analyzed in each of the cases. Blood was drawn for routine clinical monitoring on each subject after they had been on PN for six weeks or more.

This is the first step towards raising awareness of the potential problem. It is our hope that this will provide initial evidence to help guide Health Canada's decision regarding regulations on AL content in PN solutions in Canada.
OBJECTIVES: Hearing loss is the inability to hear speech or sounds well, owing to a number of causes. This study aimed to simultaneously determine the prevalence, incidence, and the Gap between them in hearing loss in South Korean patients at the same point in time as well as to identify patients who have not recovered from hearing loss.
METHODS: We examined the prevalence and incidence of patients diagnosed with hearing loss in the National Health Insurance Service database over an 11-year period from 2010 to 2020. The difference between the prevalence and the incidence was defined in this study as the term "Gap". Gap is the number of patients converted into the number of patients per 100,000 people by subtracting the incidence from the prevalence. Clinical characteristics such as sex and age per 100,000 individuals were examined.
RESULTS: As of 2020, the domestic prevalence obtained in this study was 1.84%, increasing annually, and the prevalence increased with age to 4.10% among those over 60. The domestic incidence was 1.57%, increasing annually, and the incidence increased with age to 3.36% for those over 60s. The Gap was 0.27%, showing a steady increase from 2011 to 2020 with a corresponding increase in insurance benefit expenses.
CONCLUSION: To fully understand the burden of hearing loss and develop effective prevention and treatment strategies, it is important to measure the Gap between its prevalence and incidence. This Gap means a lot because hearing loss is an irreversible disease. Gap represents patients who have already been diagnosed with hearing loss and are being diagnosed every year, indicating that the number of patients who do not recover is increasing. In other words, the increase in Gap meant that there were many patients who constantly visited the hospital for diagnosis of hearing loss.
The NHS needs effective quality improvement interventions to be put into clinical practice, which requires effective behaviour change interventions. Intervention modelling experiments (IMEs) are a way of exploring and refining an intervention before moving to a full-scale trial. They do this by delivering key elements of the intervention in a simulation that approximates clinical practice by, for example, presenting GPs with a clinical scenario about making a treatment decision. Earlier IMEs have been paper-based, which limits what can be done in the simulation.

Web-based IMEs provide the potential for better clinical simulations, which have the potential to lead to better interventions. The current proposal will run a full, web-based IME involving 250 GPs that will advance the methodology of IMEs by directly comparing results with an earlier paper-based IME. Moreover, the web-based IME will evaluate an intervention that can be put into a full-scale trial that aims to reduce antibiotic prescribing in primary care. Reducing inappropriate prescribing of antibiotics in general practice is a national priority; indeed, antibiotic use is increasing in the UK and Scotland's prescribing is second highest amongst UK administrations. More effective behaviour change interventions are needed and this proposal will develop one such intervention and a system to model and test future interventions. This system will be applicable to any situation in the NHS where behaviour needs to be modified, including interventions aimed directly at the public.
PURPOSE:The titled extract which is extracted from Laurencia obtusa belonging to the genus SOZO of red algae. CONSTITUTION:The whole marine algae of Laurencia obtusa belonging to the genus SOZO of red algae is used as a raw material, and dried in the shade until it loses no flexibility while avoiding direct rays of the sun. It is extracted with a hydrophilic organic solvent such as methanol, etc. The extract is dissolved in a hydrophobic organic solvent such as carbon tetrachloride, etc., washed with water, and washed with an alkali aqueous solution, and an acidic aqueous solution. Then, the extract is adsorbed on an active adsorbent (e.g., silica gel, alumina, active carbon, zeolite, cellulose, etc.). In the operation, preferably the extract is concentrated, then dissolved in a nonpolar solvent and adsorbed. then, it is eluted with a nonpolar organic solvent such as benzene, etc., and a component eluted with the solvent is removed. It is eluted with a polar organic colvent, to give an extract having antitumor activity. It has high activity, so it is diluted by a proper method and used.
Cellular surface receptors exist in an equilibrium between an inactive and an active state. To date, prior art approaches to studying receptor function and screening receptors for new drugs focused on first identifying the endogenous ligand for the receptor (or a synthetic substitute) and then identifying antagonists to the receptor existing in an inactive structural conformation. It has now been recognized that very valuable information relevant to treatment of diseases caused by receptors can be directly obtained by identifying compounds which act as inverse agonists to constitutively activated forms of the receptor; i.e., those in which the equilibrium has been shifted towards the active state. Methods to constitutively activate receptors are used to specify the genetic information coding for receptors which are then expressed in appropriate expression systems. Assays which measure the cellular response elicited by compounds acting on the receptors can identify both inverse agonists and agonists of the receptor. High throughput screening may be used to rapidly identify these compounds. A particulary relevant feature is that modulators of receptor action can be identified with no prior knowledge of the endogenous ligand or receptor function. The method of the invention is particularly applicable to orphan receptors.
The invention relates to a new method for combating tumor illnesses through the use of molecular biological associations during formation of the tumor. The aim of the invention is to develop a method for controlling the regulation of β-catenine in body cells. The object of the invention is a new protein which bonds to β-catenine and the subsequent cytoplasmic decomposition of said protein. This protein has the amino-acid sequence according to FIG.  1  and is designated as conductine. Agents for diagnosing and treating tumor illnesses are developed from the occurrence and the action of conductine in body cells.
An anthranilic acid derivative represented by the general formula (X) [wherein R represents hydrogen or a carboxy-protecting group; R represents optionally substituted phenyl, a heterocyclic group, etc.; R represents optionally substituted phenyl, a monocyclic heterocyclic group, etc.; X represents carbonyl, etc.; X represents optionally substituted alkylene, a bond, etc.; X represents oxygen, a bond, etc.; and X represents a group represented by the general formula -X-X- or -X-X- (wherein X means oxygen, a bond, etc.; and X means optionally substituted alkylene, a bond, etc.)] or a salt of the derivative. The derivative or salt has an MMP-13 production inhibitory activity and is hence useful as a therapeutic agent for articular rheumatisum, osteoarthritis, cancer, etc.
Urban children with asthma are at high risk for short sleep, due to an environment that jeopardizes sleep and asthma management. Further, this group suffers from altered immune balance, a key biological process contributing to individual differences in asthma morbidity and sleep health. Allergic asthma is a chronic inflammatory disorder driven primarily by disturbed T helper 1 (Th1)/ 2 (Th2) cytokine balance marked by Th2 cytokine (IL-4, IL-5 and/or IL-13) predominance. Experimental findings in healthy adults show that shortened sleep increases inflammatory cytokine (e.g., IL-6) and certain Th2 cytokine levels and that recovery sleep following sleep restriction promotes a return to immune balance. Whether sleep duration plays a key role in immune function and associated asthma activity in urban children with asthma remains a scientific gap. The researchers use an experimental design that targets sleep duration, because (1) the urban environment and asthma symptoms interact to shorten sleep, (2) sleep duration is a modifiable behavior overlooked in clinical care of urban children with asthma, and (3) experimental data are critical to test a causal link for sleep duration as a mechanism underlying immune balance and asthma.

The research team will enroll urban children (N=204; ages 7-11 years) with persistent allergic asthma and adequate sleep duration (9-11 h) who will complete a 4-week within-subjects protocol that includes 3 scheduled experimental sleep conditions: (1) 1 week stabilized sleep (individualized; 9-11 h time in bed), (2) 1 week shortened sleep (1.5 h decrease in time in bed), and (3) 2 weeks recovery sleep (1.5 h increase in time in bed). Sleep duration (actigraphy) and lung function (home spirometry) will be monitored daily and assess immune biomarkers weekly and at the midpoint of shortened sleep. To control time-in-study effects, 1/3 of the sample will receive only the stabilized sleep schedule across the 4-week protocol. In this project, the researchers will study only urban children with allergic asthma who obtain sufficient sleep (9-11 h, within national guidelines). The shortened sleep protocol will model the sleep loss that urban children with asthma can experience due to asthma and/or urban context. Additionally, the recovery sleep protocol simulates a sleep optimization intervention following shortened sleep in a well-controlled approach.

The first aim of the study is to examine the effects of shortened sleep on immune balance \[e.g., Th1 (Interferon-IFN gamma)/Th2 (Interleukin-IL-4, IL-5, IL-13)R and plasma IL-6 levels\]. The second aim involves determining the effects of recovery sleep on immune balance. The third aim involves examining the extent to which changes in immune balance are associated with changes in asthma-related lung function (changes in FEV1) under conditions of shortened and recovery sleep. Results from this study ultimately will support the development feasible, ecologically valid, and clinically meaningful interventions to optimize sleep duration, immune balance, and asthma in this at-risk group.